Financial Result fpr half year ended on 30th September 2025

Revenue growth above 20%Profit growth above 25%Related-party transactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.7%Reaction day

₹4.70

prior close

₹4.46

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+5.2% vs market

Trading & Distributors peers, median of 125sector-0.7%+5.3% vs sector

On the reaction day the stock moved 5.2 pts more than Nifty Microcap 250 and 5.3 pts more than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.1

10m

+0.4

15m

+0.4

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.7-0.5+5.2-0.7+5.3

Next day

+8.3-1.7+10.0-1.3+9.6

+13.0-0.7+13.7-1.9+14.9

+16.4-0.2+16.6-1.9+18.3

+22.1-0.7+22.8-1.7+23.8

+25.1+0.3+24.8-1.5+26.6

+27.7+0.9+26.8-0.8+28.5

15d

-5.5+1.4-6.9-2.1-3.4

-12.6+0.3-12.8-2.4-10.2

-38.9-4.5-34.5-8.9-30.0

-38.1-7.4-30.7-12.3-25.8

UpDownMarket · Nifty Microcap 250Sector · Trading & Distributors peers, median of 125Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Evoq Remedies reported revenue from operations of Rs 2,550.68 lakhs for H1 FY26, nearly doubling from Rs 1,175.67 lakhs in H1 FY25 (around 117% YoY growth). The company swung back to a small profit of Rs 5.43 lakhs (EPS Rs 0.02) compared to a loss of Rs 162.44 lakhs in the same period last year, though profit fell sharply from the Rs 171.26 lakhs earned in FY25 as a whole. The auditor (H Thakkar & Co. LLP) issued a limited review report attaching an 8-point Annexure flagging serious concerns: an ongoing SEBI investigation and show-cause notice over a Rs 9.21 crore preferential allotment, a Rs 655.03 lakh GST demand, Rs 39.99 lakh disputed income tax demand, Rs 38.23 lakh unpaid TDS/TCS, Rs 668.86 lakh of loans to related parties without proper Companies Act compliance, and Rs 1,250.87 lakh of unconfirmed supplier advances. Trade receivables remain elevated at Rs 1,969 lakhs while operating cash flow turned marginally positive at Rs 9.37 lakhs.

Likely market impact

While top-line growth is strong and the company returned to profitability, the auditor's annexure highlights significant regulatory, tax, and related-party risks that could materially affect the company's financial position. Shareholders should weigh the revenue momentum against SEBI proceedings, pending tax/GST demands, and weak internal controls before drawing conclusions.

By the numbersStandalone · Q2 FY26 vs Q2 FY25

	Q2 FY26	Q2 FY25	Change
Revenue	₹25.51 Cr	₹0.00 Cr	turned positive
Operating profit	−₹0.98 Cr	−₹1.64 Cr	loss narrowed
Profit after tax	—	—	—
EBITDA margin	—	—	—

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.